About Ignyta
Ignyta is a company based in San Diego (United States) founded in 2011 by Gary Firestein was acquired by Roche in December 2017. Ignyta has raised $96.87 million across 9 funding rounds from investors including Roche, Teva Pharmaceuticals and Great Point Partners. Ignyta operates in a competitive market with competitors including TScan Therapeutics, Imbed Biosciences, GigaGen, Shattuck Labs and Boundless Bio, among others.
- Headquarter San Diego, United States
- Founders Gary Firestein
- Stage Public
- SectorsHealthcareTechnology
- Website ignyta.com
- Social X
- Acquired by Roche (Dec 2017)
- Legal Name Ignyta, Inc.
- Date of Incorporation 15 Dec, 2008
- Jurisdiction Mumbai, Maharashtra, India
Associated legal entities of Ignyta
Ignyta operates through Ta Associates Advisory Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Ta Associates Advisory Private Limited CIN U74900MH2008PTC188893 | Active | 15 Dec 2008 | Mumbai, Maharashtra | ₹205 Cr | – | 3 | View details |
Funding Insights of Ignyta
Ignyta has successfully raised a total of $96.87M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $160 million completed in October 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $96.87M
- Total Rounds 9
- Last Round Post-IPO — $160M
- First Round $250,000
(Oct 2011)
- Investors Count 4
All 9 funding rounds of Ignyta with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2017 | $160M | Post-IPO | – | – | – |
| May 2016 | – | Post-IPO | – | – | |
| Nov 2015 | $30M | Post-IPO | – | – | – |
| Mar 2015 | $42M | Post-IPO | – | – | |
| Dec 2013 | $7.62M | Series B | – | – | – |
| Dec 2013 | $54M | Series B | – | – | – |
| Oct 2013 | $29.5M | Series B | – | – | – |
| Jan 2013 | $5.51M | Series A | – | City Hill Ventures, Colt Ventures | – |
| Oct 2011 | $250,000 | Seed | – | – | – |
5 investors in total: 5 institutional.
Investors in Ignyta
Ignyta has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Roche, Teva Pharmaceuticals and Great Point Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity firm focused on company buyouts | – | gppfunds.com | Greenwich, United States | |
- | – | cityhillventures.com | - | |
Private equity investments are managed by this USA-based firm. | – | coltventures.com | Dallas, United States | |
Generic pharmaceuticals are manufactured by Teva Pharmaceuticals. | 1901 | tevapharm.com | Petah Tikva, Israel | |
Pharmaceuticals and diagnostics kits are developed for various diseases. | 1896 | roche.com | Basel, Switzerland |
Investor details for Ignyta
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Ta Associates Advisory Private Limited (Ignyta)
Ta Associates Advisory Private Limited is the primary company behind Ignyta. The board of Ta Associates Advisory Private Limited currently have 3 directors; the longest-serving is Melanie Rae Toomey, appointed in 2015. 8 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Melanie Rae Toomey DIN 07103302 | Director | 02 Mar 2015 | 11 yrs 7 mo | Ta Associates Advisory Private Limited |
| Ravindranath Menon Kizhakkepat Bhaskaran DIN 02579565 | Director | 01 Feb 2021 | 5 yrs 8 mo | Ta Associates Advisory Private Limited |
| Jennifer Ami Barbetta DIN 10709061 | Director | 25 Jul 2024 | 2 yrs 2 mo | Ta Associates Advisory Private Limited |
People of Ignyta
1 people are tracked at Ignyta (1 in leadership).
| Name | Role | Group |
|---|---|---|
Gary Firestein | Co-Founder | Leadership |
Complete people profiles for Ignyta
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Ignyta
Figures of Ta Associates Advisory Private Limited, the primary company behind Ignyta, for FY 2025. Revenue was ₹205 Cr (+92% year on year). Net profit was ₹25.37 Cr (12% margin). EBITDA was ₹35.32 Cr (17% margin). Revenue has grown at a compounded annual rate of +46% over three years and +34% over five years.
- ₹205 CrRevenue · FY 2025 · +92% YoY
- ₹25.37 CrNet profit · 12% margin
- ₹35.32 CrEBITDA · 17% margin
- ₹2.56 CrPaid-up capital
- +46%Revenue CAGR, 3 years
- +34%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Ta Associates Advisory Private Limited are on its company page.
Detailed financial statements for Ignyta
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Ignyta
5 dated milestones of Ignyta across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Ignyta is founded.
- Funding First funding round of $250K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $160.0M.
- Exit Acquired by Roche.
Competitors of Ignyta
Ignyta operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as TScan Therapeutics, Imbed Biosciences, GigaGen, Shattuck Labs and Boundless Bio, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tscan.com | 1995 | Boston, United States | $158.3M | 154 | T cell-based treatments for immunological and oncological disorders are developed. | |
| imbedbio.com | 2010 | Madison, United States | $22.7M | 35 | Nanotech-based wound care products are developed and provided. | |
| gigagen.com | 2011 | San Francisco, United States | $36.13M | 36 | T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | |
| shattucklabs.com | 2016 | Austin, United States | $165.4M | 89 | An immunotherapy platform for oncology and other diseases is developed. | |
| boundlessbio.com | 2018 | San Diego, United States | $251.99M | 29 | Therapeutics for cancer are developed by targeting ecDNA. | |
| boltbio.com | 2015 | Redwood, United States | $177.49M | 94 | T-cell therapies for cancer treatment are developed by Bolt Biotherapeutics. | |
| jacobiopharma.com | 2015 | Beijing, China | $55M | – | Small molecule therapeutics for cancer treatment are developed. |
Detailed competitors of Ignyta
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Ignyta
Websites that share an audience with Ignyta (ignyta.com).
Websites whose visitors overlap most with Ignyta. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| ichorms.com | 100% | 5.3K | #8,265,520 | View details | |
| adaptivebiotech.com | 98% | 63.9K | #807,876 | View details | |
| proteostasis.com | 90% | – | – | View details | |
| bellicum.com | 89% | 1.8K | #8,642,421 | View details | |
| verastem.com | 89% | 7.1K | #3,436,777 | View details |
Latest news on Ignyta
Complete news archive for Ignyta
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Ignyta
10 companies that operate in the same segment as Ignyta (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Ignyta
Ignyta was founded in 2011.
Ignyta is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Ignyta is a funded company, having raised a total of $96.87M across 9 funding rounds to date. The company's 1st funding round was a Seed of $250K, raised on Oct 2011.
The primary company behind Ignyta, Ta Associates Advisory Private Limited, reported revenue of ₹205 Cr for FY 2025, up 92% year on year.
Ignyta employs an integrated RxDx strategy of combining highly targeted drug discovery and development with companion diagnostics for patient selection. The main drugs in its pipeline include - Entrectinib (An orally available, selective tyrosine kinase inhibitor), Taladegib (A small molecule hedgehogsmoothened antagonist), RXDX-105 (small-molecule multikinase inhibitor), RXDX-107 (an alkyl ester of bendamustine encapsulated in human serum albumin (HSA) to form nanoparticles). Most of these drugs are at an early clinical stage. On the diagnostic side, Ignyta has launched Trailblaze Pharos, a multiplex assay for identifying actionable gene rearrangements in solid tumors that can be treated with entrectinib.
Ignyta's top competitors include Imbed Biosciences, GigaGen and Shattuck Labs.
Ignyta has 5 investors. Key investors include Roche, Teva Pharmaceuticals, Great Point Partners, City Hill Ventures, and Colt Ventures.
Ignyta operates through Ta Associates Advisory Private Limited.
Yes. Ignyta was acquired by Roche in December 2017.
The legal entities of Ignyta currently have 3 directors, including Melanie Rae Toomey, Ravindranath Menon Kizhakkepat Bhaskaran, Jennifer Ami Barbetta.